期刊文献+

UPLC法同时测定盐酸阿糖胞苷原料药的含量和有关物质 被引量:4

Simultaneous Determination of Cytarabine Hydrochloride and Related Substances by UPLC
原文传递
导出
摘要 目的:建立同时测定盐酸阿糖胞苷原料药的含量和有关物质的方法。方法:采用超高效液相色谱法。色谱柱为Inertsil ODS-3 C18流动相为磷酸盐缓冲液-甲醇(梯度洗脱),流速为0.8ml/min,检测波长为254nm,柱温为40℃,进样量为10μl。结果:尿嘧啶、尿苷、阿糖尿苷、盐酸阿糖胞苷检测质量浓度分别在0.1008~20.16、0.1~20.12、0.0956~19.12、0.1~20.004μg/ml范围内与各自峰面积积分值呈良好的线性关系(r=0.9999、0.9998、0.9999、0.9999);精密度、稳定性、重复性试验的RSD≤0.79%;尿嘧啶、尿苷、阿糖尿苷平均加样回收率为103.8%、102.2%、99.7%,RSD分别为2.44%、2.69%、3.16%(n=9)。结论:该方法准确、灵敏度高、专属性强、重复性好.可用于盐酸阿糖胞苷原料药的质量控制。 OBJECTIVE: To establish a method for simultaneous determination of cytarabine hydrochloride and related substance. METHODS: UPLC method was adopted. The determination was performed on Inertsil ODS-3 CIS column with mobile phase consisted of phosphate buffer-methanol (gradient elution) at the flow rate of 0.8 ml/min; the detection wavelength was set at 254 nm and the column temperature was 40℃. The sample size was 10μl. RESULTS: The liner ranges were 0.100 8-20.16 μg/ml for uracil (r=0.999 9), 0.1-20.12 μg/ml for uridine (r=0.999 8), 0.0956-19.12 ug/ml for 1-β-D-arabino furanosyl-uracil (r=0.999 9) and 0.1-20.004 μg/ml for cytarabine hydrochloride (r=0.999 9), respectively. RSD of precision, stability and reproducibility tests were all lower than 0.79%; average recoveries of uracil, wridine and 1-β-D-arabino furanosyl-uracil were 103.8% (RSD=2.44%, n=9), 102.2% (RSD=2.69%, n=9) and 99.7% (RSD=3.16%, n=9). CONCLUSIONS: The method is accurate, sensitive, specific and reproducible, and can be used for the quality control of cytarabine hydrochloride.
出处 《中国药房》 CAS CSCD 2014年第12期1137-1140,共4页 China Pharmacy
关键词 盐酸阿糖胞苷 尿嘧啶 尿苷 阿糖尿苷 超高效液相色谱法 含量测定 Cytarabine hydrochloride Uracil Uridine 1-β-D- arabino furanosyl -uracil UPLC Content determination
  • 相关文献

参考文献8

二级参考文献41

共引文献9

同被引文献43

  • 1文海若,闫明,王亚楠,王翀,耿兴超,朱炯,张河战,王雪.药物杂质遗传毒性评价策略与监管研究[J].中国药事,2020,34(2):131-140. 被引量:9
  • 2吴玉秀.医院冷藏药品院内分发和病区管理的问题与对策[J].世界最新医学信息文摘,2019,0(79):9-10. 被引量:1
  • 3蔡东,商琳琳,贾云宏,邹军.胞嘧啶的合成研究进展[J].化工中间体,2009,5(2):14-17. 被引量:11
  • 4李宝宗.嘧啶及其异构体的密度泛函理论研究[J].化学研究与应用,2004,16(6):792-794. 被引量:5
  • 5李永,渠桂荣,刘启宾,韩素辉.胞苷的合成[J].精细化工,2004,21(12):917-919. 被引量:3
  • 6冀亚飞,徐万美.改进的胞苷合成[J].化学世界,2007,48(1):59-60. 被引量:1
  • 7Makielski JC, Valdivia CR. Ranolazine and late cardiac sodium current-a therapeutic target for angina, arrhythmia and more [ J ]. Br J Pharmacol, 2006, 148: 4? 6,.
  • 8Vakamulla Malati, Anumala Raghupati Reddy, K. Mukkanti, et al. A no- vel reverse phase stability indicating RP-UPLC method for the quantitative determination of fifteen related substances in Ranolazine drug substance and drug product[J]. Talanta,2012,97:563-573.
  • 9Ch. Krishnaiah, M. Vishnu Murthy, Ramesh Kumar, etal. Development of a stability-indicating UPLC method for determining olanzapine and its associ- ated degradation products present in active pharmaceutical ingredients and pharmaceutical dosage form[ J]. Journal of Pharmaceutical and Biomedical Analysis ,2011,54:667-673.
  • 10A. Nageswari,K. V. S. R. Krishna Reddy,K. Mukkanti. Stability-indica- ting UPLC method for determination of hnatinlb Mesylate and their degrada- tion products in active pharmaceutical ingredient and pharmaceutical dosage forms [ J ]. Joumal of Pharmaceutical and Biomedical Analysis, 2012,66 : 109-115.

引证文献4

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部